- Oral presentation
- Open Access
Induction of HIV-specific T-cell responses by gag
https://doi.org/10.1186/1742-4690-3-S1-S78
© Van Gulck et al; licensee BioMed Central Ltd. 2006
- Published: 21 December 2006
Keywords
- Peptide
- Infectious Disease
- Cancer Research
- Treated Subject
- Delay Evolution
Objectives
In order to suppress HIV and delay evolution to AIDS, antigen-loaded DC might be useful to boost and broaden HIV-1-specific T-cell responses, which are dysfunctional in HIV infection.
Methods
DC (from 15 treatment-naïve and 15 HAART-treated HIV-1-infected patients) were electroporated with codon-optimized mRNA encoding consensus HxB-2 Gag. These DC were co-cultured for 1 week with autologous peripheral blood leucocytes. Expansion of specific T-cells was measured by ELISPOT, using a pool of overlapping peptides, spanning HxB-2 Gag.
Results
Expansion of specific T cells producing IFN-γ, IL-2 and perforin was seen. Comparing the response between 12 treated and 12 naïve patients, matched in absolute CD4+ T-cell count, showed that the response was higher in treated subjects for IFN-γ and IL-2 but not for perforin. HxB-2 peptides induced IFN-γ in CD4+ and CD8+ T-cell subsets purified following coculture, IL-2 was only secreted by CD4+ T-cells and perforin was dominantly secreted by CD8+ T-cells. Remarkably, the perforin response in naïve persons was negatively correlated with the absolute CD4+ and CD8+ T-cell count. The nadir CD4+ T-cell count in treated subjects was positively correlated with the IL-2 response and negatively correlated with the perforin response.
Conclusion
HxB-2 gag mRNA-transfected DC from treated and naïve subjects have the capacity to induce secondary T-cell responses. These results of this and another study, where we showed that T-cells from naïve HIV-infected subjects can be triggered by DC electroporated with autologous gag mRNA (Blood 2006;107:1818-27), open the perspective for a DC immunotherapy of HIV disease.
Authors’ Affiliations
Copyright
This article is published under license to BioMed Central Ltd.